Other safety alerts
|
| |
| Singapore: Update to Fact Sheets of Paxlovid (nirmatrelvir 300mg co-packaged with ritonavir 100mg) tablets with new safety information and microbiological data |
| |
Health Sciences Authority (HSA) announces a Dear Healthcare Professional Letter has been issued by Pfizer Private Limited to inform healthcare professionals of updates to the Paxlovid Fact Sheets for Healthcare Providers and Patients/Caregivers. The updates to the Fact Sheets include the addition of anaphylaxis as adverse reaction, addition of new drug interactions and antiviral data. Healthcare professionals are advised to assess patient's medication and supplement list before starting Paxlovid treatment, and to inform patients to discontinue Paxlovid immediately if they experience any symptoms of allergic reactions.
Please refer to the following website in HSA for details:
http://www.hsa.gov.sg/announcements/dear-healthcare-professional-letter/update-to-fact-sheets-of-paxlovid-(nirmatrelvir-300mg-co-packaged-with-ritonavir-100mg)-tablets-with-new-safety-information-and-microbiological-data
In Hong Kong, Paxlovid Tablets (HK-67360) is a pharmaceutical product registered by Pfizer Corporation Hong Kong Limited. The product is a prescription-only medicine. So far, the Department of Health (DH) has received 58 cases of adverse drug reaction related to Paxlovid, but these cases were not related to anaphylaxis. In light of the above HSA’s announcement, letters to inform local healthcare professionals will be issued. The DH will remain vigilant on safety update of the product issued by other overseas drug regulatory authorities for consideration of any action deemed necessary.
Ends/Friday, Dec 16, 2022
Issued at HKT 15:00
|
| |
|
